Given the promising results of pioglitazone in human leukemia, it was of particular interest to evaluate whether there is a difference in the expression level of PPARγ in acute myeloid leukemia (AML) patients and also to examine the therapeutic efficacy of pioglitazone in AML‐derived U937 cells. The gene discussed is PPARG; the disease is acute myeloid leukemia.